Abstract
We believe that PCO patients can achieve good results in IVF cycles, provided that stimulation protocols appropriate to their hormonal profiles are used.
The dose of gonadotropin used seems to be more important than the type of gonadotropin. If there is a risk of ovarian hyperstimulation, it is useful to employ one of the strategies recommended to prevent development of genuine OHS, which may endanger the patient’s health.
MeSH terms
-
Abortion, Spontaneous / prevention & control*
-
Albumins / therapeutic use
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Buserelin / therapeutic use
-
Estradiol / metabolism
-
Female
-
Fertilization in Vitro / methods*
-
Fertilization in Vitro / statistics & numerical data
-
Follicle Stimulating Hormone / therapeutic use
-
Gonadotropin-Releasing Hormone / analogs & derivatives
-
Gonadotropin-Releasing Hormone / therapeutic use
-
Growth Hormone / therapeutic use
-
Humans
-
Luteinizing Hormone / metabolism
-
Menotropins / therapeutic use
-
Oocytes / drug effects
-
Oocytes / physiology*
-
Ovarian Hyperstimulation Syndrome / metabolism*
-
Ovarian Hyperstimulation Syndrome / prevention & control
-
Polycystic Ovary Syndrome / metabolism
-
Polycystic Ovary Syndrome / therapy*
-
Pregnancy
Substances
-
Albumins
-
Antineoplastic Agents, Hormonal
-
Gonadotropin-Releasing Hormone
-
Estradiol
-
Menotropins
-
Luteinizing Hormone
-
Follicle Stimulating Hormone
-
Growth Hormone
-
Buserelin